Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?

Ihle-Hansen H, Ihle-Hansen H, Blauenfeldt RA, Dawson J, Diederichsen SZ, Hagberg G

Open source

DOI
10.3389/fstro.2026.1918465
Published
2026
Container
Frontiers in stroke
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fstro.2026.1918465,
  title = {Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?},
  author = {Ihle-Hansen H and Ihle-Hansen H and Blauenfeldt RA and Dawson J and Diederichsen SZ and Hagberg G},
  year = {2026},
  journal = {Frontiers in stroke},
  doi = {10.3389/fstro.2026.1918465},
  url = {https://doi.org/10.3389/fstro.2026.1918465}
}

RIS

TY  - JOUR
TI  - Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?
AU  - Ihle-Hansen H
AU  - Ihle-Hansen H
AU  - Blauenfeldt RA
AU  - Dawson J
AU  - Diederichsen SZ
AU  - Hagberg G
PY  - 2026
JO  - Frontiers in stroke
DO  - 10.3389/fstro.2026.1918465
UR  - https://doi.org/10.3389/fstro.2026.1918465
ER  - 

APA

H, I., H, I., RA, B., J, D., SZ, D., & G, H. (2026). Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?. Frontiers in stroke. https://doi.org/10.3389/fstro.2026.1918465

Source records